The ‘Next-Generation’ Hyaluronic Acid Dermal Filler Products by Allergan to be Available in January 2007
Sunday, October 15th, 2006Allergan, Inc. (NYSE:AGN), the maker of BOTOX(R) Cosmetic (Botulinum
Toxin Type A), today announced it is launching its ‘next-generation’
hyaluronic acid dermal filler products, JUVEDERM(TM) ULTRA and
JUVEDERM(TM) ULTRA PLUS, through an experience trial involving a group
of physicians with expertise in facial aesthetics, in advance of
nationwide product availability in January 2007. Allergan will begin
accepting physician pre-orders for the products on November 1, 2006 via
its nationwide sales force.
Pricing of both products will be announced to physicians via the
Allergan sales force starting November 1, 2006. The JUVEDERM(TM)
experience trial is a multi-center, open-label trial, designed to gain
relevant information on physicians’ use of JUVEDERM(TM) ULTRA and
JUVEDERM(TM) ULTRA PLUS and evaluate the persistence of and patient
satisfaction with the products in daily clinical practice. The U.S.
Food and Drug Administration approved the JUVEDERM(TM) dermal filler
family of products in June 2006. JUVEDERM(TM) ULTRA is a highly
cross-linked formulation for more versatility in contouring and
volumizing of facial wrinkles and folds.
Read More: Cosmetic Surgery